Publication

Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer.

Authors not recorded

J Exp Med2019PMID 30683736PMC6363423stubpubmedPublished

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (6)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 6

cancerHead and Neck Squamous Cell Carcinomacivic_curation1.00
drugAspirincivic_curation1.00
drugCelecoxibcivic_curation1.00
drugSulindaccivic_curation1.00
genePIK3CAcivic_curation1.00
variantPIK3CA Mutationcivic_curation1.00

Curated evidence

Evidence citing this paper (2)

civicCuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
PIK3CA Amplification1
Aspirin + Ibuprofen + SulindacSubstitutes	Head and Neck Squamous Cell Carcinoma	Predictive	B	Supports Sensitivity Response	3	submitted	EID7186 In this retrospective study, the impact of nonsteroidal anti-inflammatory drugs (NSAID) on survival in PIK3CA-altered HNSCC patients (N=266) was assessed. 37 of 266 (14%) patients harbored a mutation,… (full text at CIViC) PMID 30683736 · Hedberg et al., 2019 · Open in CIViC	civic
PIK3CA Mutation1
Aspirin + Celecoxib + SulindacSubstitutes	Head and Neck Squamous Cell Carcinoma	Predictive	B	Supports Sensitivity Response	3	accepted	EID7185 In this retrospective study, the impact of nonsteroidal anti-inflammatory drugs (NSAID) on survival in PIK3CA-altered HNSCC patients (N=266) was assessed. 37 of 266 (14%) patients harbored a mutation,… (full text at CIViC) PMID 30683736 · Hedberg et al., 2019 · Open in CIViC	civic